Search Results

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

• Authors : Tempus AI

• Source: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults

Record details

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers (HN-Bio 02)

• Source: HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

Record details

In-Flight Radiometric Calibration of Gas Absorption Bands for the Gaofen-5 (02) DPC Using Sunglint.

• Authors : Zhu, Sifeng^1,2,3 (AUTHOR); Zhang, Liguo² (AUTHOR); Xie, Yanqing^2,3 (AUTHOR)

• Source: Remote Sensing. Nov2025, Vol. 17 Issue 21, p3558. 16p.

Record details

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX (PANACHE 02)

• Authors : Partenariat de Recherche en Oncologie DIGEstive - PRODIGE; Federation de recherche en chirurgie digestive (FRENCH)

• Source: Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX - A Multicenter, FRENCH-PRODIGE Randomized

Record details

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

• Authors : Nanjing Bioheng Biotech Co., Ltd.; MEI HENG, Clinical Professor

• Source: A Study on the Efficacy, Safety and Cellular Pharmacokinetics of RD13-02 Cell Injection in Patients With Relapsed or Refractory CD7-positive Hematological Malignancies

Record details

SIRAKI 02 Posthoc Analysis.

• Authors : University of Barcelona; Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Germans Trias i Pujol Hospital ...

• Source: SIRAKI02 POST-HOC ANALYSIS.Perez-Fernandez X, Ulsamer A, Camara-Rosell M, Sbraga F, Boza-Hernandez E, Moret-Ruiz E, Plata-Menchaca E, Santiago-Bautista D, Boronat-Garcia P, Gumucio-Sanguino V,

Record details

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

• Authors : University of Manchester; University of Birmingham; Royal Marsden NHS Foundation Trust

• Source: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to

Record details

Evaluación del potencial coleoptericida de extractos crudos de quitinasa recombinante ChiBlUV 02 de Bacillus licheniformis sobre Aethina tumida

• Authors : Deny de Jesús Velasco-Vique; Argel Flores-Primo; Rodolfo Quintana-Castro

Subjects: Larvas; Bioplaguicida; Veterinary medicine

• Source: Revista Mexicana de Ciencias Pecuarias, Vol 16, Iss s4 (2025)

Record details

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

• Authors : Shanghai Zhongshan Hospital

• Source: An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy

Record details

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)

• Authors : Novartis Pharmaceuticals

• Source: A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing

Record details